The DOI matches its Crossref record; 217 of the 218 references it cites were found in a registry or an index.
Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids N,N-Dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact
Open accessAbstract
Ayahuasca is a hallucinogenic botanical beverage originally used by indigenous Amazonian tribes in religious ceremonies and therapeutic practices. While ethnobotanical surveys still indicate its spiritual and medicinal uses, consumption of ayahuasca has been progressively related with a recreational purpose, particularly in Western societies. The ayahuasca aqueous concoction is typically prepared from the leaves of the N,N-dimethyltryptamine (DMT)-containing Psychotria viridis, and the stem and bark of Banisteriopsis caapi, the plant source of harmala alkaloids. Herein, the toxicokinetics and toxicodynamics of the psychoactive DMT and harmala alkaloids harmine, harmaline and tetrahydroharmine, are comprehensively covered, particularly emphasizing the psychological, physiological, and toxic effects deriving from their concomitant intake. Potential therapeutic utility, particularly in mental and psychiatric disorders, and forensic aspects of DMT and ayahuasca are also reviewed and discussed. Following administration of ayahuasca, DMT is rapidly absorbed and distributed. Harmala alkaloids act as potent inhibitors of monoamine oxidase A (MAO-A), preventing extensive first-pass degradation of DMT into 3-indole-acetic acid (3-IAA), and enabling sufficient amounts of DMT to reach the brain. DMT has affinity for a variety of serotonergic and non-serotonergic receptors, though its psychotropic effects are mainly related with the activation of serotonin receptors type 2A (5-HT2A). Mildly to rarely severe psychedelic adverse effects are reported for ayahuasca or its alkaloids individually, but abuse does not lead to dependence or tolerance. For a long time, the evidence has pointed to potential psychotherapeutic benefits in the treatment of depression, anxiety, and substance abuse disorders; and although misuse of ayahuasca has been diverting attention away from such clinical potential, research onto its therapeutic effects has now strongly resurged.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Harmine as a MAO-I was chosen, because it’s a major psychoactive molecule of the ayahuasca brew with a favorable side effect profile, e.g., lower toxicity compared to harmaline, and because it’s selective and reversible (55).”
From Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects (2024) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Predicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Jones, M. W., Errington, M. L., French, P. J., Fine, A., Bliss, T., Garel, S., Charnay, P., Bozon, B., Laroche, S., & Davis, S. (2001) · Nature Neuroscience · doi:10.1038/85138 · Cited by 925
González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925
Pompeiano, M., Palacios, J. M., & Mengod, G. (1994) · Molecular Brain Research · doi:10.1016/0169-328x(94)90223-2 · Cited by 870
Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001356 · Cited by 852
Serotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739
Bunzow, J. R., Sonders, M. S., Arttamangkul, S., Harrison, L. M., Zhang, G., Quigley, D. I., Darland, T., Suchland, K. L., Pasumamula, S., Kennedy, J. L., et al. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.6.1181 · Cited by 651
The Hallucinogen N,N -Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator
Fontanilla, D., Johannessen, M., Hajipour, A. R., Cozzi, N. V., Jackson, M. B., & Ruoho, A. E. (2009) · Science · doi:10.1126/science.1166127 · Cited by 535
Osório, F. D. L., Sanches, R. F., Macedo, L. R., dos Santos, R. G., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A., & Hallak, J. E. (2015) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2014-1496 · Cited by 488
Sanches, R. F., de Lima Osório, F., dos Santos, R. G., Macedo, L. R. H., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000436 · Cited by 466
O’Donovan, K. J., Tourtellotte, W. G., Milbrandt, J., & Baraban, J. M. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01343-5 · Cited by 457
Strassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020022002 · Cited by 453
Role of the Serotonergic System in the Pathogenesis of Major Depression and Suicidal Behavior
Mann, J. J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00040-8 · Cited by 443
Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens
Halberstadt, A. L., & Geyer, M. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.017 · Cited by 435
Hendricks, P. S., Thorne, C. B., Clark, C. B., Coombs, D. W., & Johnson, M. W. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565653 · Cited by 410
McKenna, D. J., Towers, G. H. N., & Abbott, F. (1984) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(84)90003-5 · Cited by 398
Riba, J., Valle, M., Urbano, G., Yritia, M., Morte, A., & Barbanoj, M. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049882 · Cited by 390
Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands
Cobos, E. J., Entrena, J. M., Nieto, F. R., Cendán, C. M., & Pozo, E. (2008) · Current Neuropharmacology · doi:10.2174/157015908787386113 · Cited by 377
Psychedelics and mental health: a population study
Krebs, T. S., & Johansen, P.-Ø. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063972 · Cited by 347
Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta‐Analysis
Cameron, C. G., Kelly, S., Hsieh, S., Murphy, M., Chen, L., Kotb, A., Peterson, J., Coyle, D., Skidmore, B., Gomes, T., et al. (2015) · Headache The Journal of Head and Face Pain · doi:10.1111/head.12601 · Cited by 339
Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil.
GROB, C. S., McKENNA, D. J., CALLAWAY, J. C., BRITO, G. S., NEVES, E. S., OBERLAENDER, G., SAIDE, O. L., LABIGALINI, E., TACLA, C., MIRANDA, C. T., et al. (1996) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199602000-00004 · Cited by 338
Psychedelics not linked to mental health problems or suicidal behavior: A population study
Johansen, P.-Ø., & Krebs, T. S. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114568039 · Cited by 330
McKenna, D. J. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.03.002 · Cited by 321
Pharmacokinetics of Hoasca alkaloids in healthy humans
Callaway, J. C., McKenna, D. J., Grob, C. S., Brito, G. S., Raymon, L. P., Poland, R. E., Andrade, E. O., Andrade, E. O., & Mash, D. C. (1999) · Journal of Ethnopharmacology · doi:10.1016/s0378-8741(98)00168-8 · Cited by 318
Bouso, J. C., González, D., Fondevila, S., Cutchet, M., Fernández, X., Ribeiro Barbosa, P. C., Alcázar-Córcoles, M. Á., Araújo, W. S., Barbanoj, M. J., Fábregas, J. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042421 · Cited by 313
The hallucinogenic world of tryptamines: an updated review
Araújo, A. M., Carvalho, F. D., Bastos, M. D. L., de Pinho, P. G., & Carvalho, M. C. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1513-x · Cited by 292
Dose-Response Study of N,N-Dimethyltryptamine in Humans
Strassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020009001 · Cited by 291
Sotelo, C., Cholley, B., Mestikawy, S. E., GOZLAN, H., & Hamon, M. (1990) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1990.tb00026.x · Cited by 285
ADVERSE REACTIONS TO PSYCHEDELIC DRUGS. A REVIEW OF THE LITERATURE
Strassman, R. (1984) · Journal of Nervous and Mental Disease · doi:10.1097/00005053-198410000-00001 · Cited by 280
The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain
Nagai, F., Nonaka, R., & Satoh Hisashi Kamimura, K. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.11.075 · Cited by 279
Neuropharmacology of N,N-dimethyltryptamine
Carbonaro, T. M., & Gatch, M. B. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.04.016 · Cited by 268
Human psychopharmacology of N,N-dimethyltryptamine
Strassman, R. J. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00081-2 · Cited by 261
Structures and mechanism of the monoamine oxidase family
Gaweska, H., & Fitzpatrick, P. F. (2011) · bmc · doi:10.1515/bmc.2011.030 · Cited by 247
Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids.
Gable, R. S. (2007) · Addiction · doi:10.1111/j.1360-0443.2006.01652.x · Cited by 244
The therapeutic potentials of Ayahuasca: possible effects against various diseases of civilization
Frecska, E., Bokor, P., & Winkelman, M. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00035 · Cited by 242
Seeing with the eyes shut: neural basis of enhanced imagery following ayahuasca ingestion.
de Araujo, D. B., Ribeiro, S., Cecchi, G. A., Carvalho, F. M., Sanchez, T. A., Pinto, J. P., de Martinis, B. S., Crippa, J. A., Hallak, J. E. C., & Santos, A. C. (2012) · Human Brain Mapping · doi:10.1002/hbm.21381 · Cited by 239
Ayahuasca: pharmacology, neuroscience and therapeutic potential
Domínguez-Clavé, E., Soler, J., Elices, M., Pascual, J. C., Álvarez, E., de la Fuente Revenga, M., Friedlander, P., Feilding, A., & Riba, J. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.03.002 · Cited by 226
Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance
Dinis-Oliveira, R. J. (2017) · Drug Metabolism Reviews · doi:10.1080/03602532.2016.1278228 · Cited by 224 · cited 1×
“Additionally, their use does not lead to dependence, nor they are consumed for long periods of time [7,8], with unusual reports of chronic use [9].”
BackgroundSelf-citationShulgin, A. T., & Shulgin, A. (1997) · Cited by 223
Hallucinogens and dissociative agents naturally growing in the United States
Halpern, J. H. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.03.003 · Cited by 222
Bouso, J. C., Palhano-Fontes, F., Rodríguez-Fornells, A., Ribeiro, S., Sanches, R., Crippa, J. A. S., Hallak, J. E. C., de Araujo, D. B., & Riba, J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.008 · Cited by 218
The globalization of ayahuasca: harm reduction or benefit maximization?
Tupper, K. W. (2008) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2006.11.001 · Cited by 212
SANTOS, R. G. D., Landeira-Fernández, J., Strassman, R. J., Motta, V., & Cruz, A. P. D. M. (2007) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2007.04.012 · Cited by 212
Glennon, R. A., Dukat, M., Grella, B. S., Hong, S., Costantino, L., Teitler, M., Smith, C., Egan, C., Davis, K., & Mattson, M. V. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00148-9 · Cited by 210
Szára, S. (1956) · Cellular and Molecular Life Sciences · doi:10.1007/bf02157378 · Cited by 203
Hamill, J., Hallak, J. E. C., Dursun, S. M., & Baker, G. B. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180125095902 · Cited by 201
Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes
McKenna, D. J., Repke, D. B., Lo, L., & Peroutka, S. J. (1990) · Neuropharmacology · doi:10.1016/0028-3908(90)90001-8 · Cited by 195
Glennon, R. A., Young, R., & Rosecrans, J. A. (1983) · European Journal of Pharmacology · doi:10.1016/0014-2999(83)90464-8 · Cited by 190
Psychological and Cognitive Effects of Long-Term Peyote Use Among Native Americans
Halpern, J. H., Sherwood, A. R., Hudson, J. I., Yurgelun-Todd, D. A., & Pope, H. G. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.038 · Cited by 187
Regulation of the dopamine transporter
Schmitt, K. C., & Reith, M. E. A. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05148.x · Cited by 186
“Ayahuasca,” the South American hallucinogenic drink: An ethnobotanical and chemical investigation
Rivier, L., & Lindgren, J. (1972) · Economic Botany · doi:10.1007/bf02860772 · Cited by 186
Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies
SANTOS, R. G. D., Bouso, J. C., & Hallak, J. E. C. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316689030 · Cited by 186
Barker, S. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00536 · Cited by 177
SANTOS, R. G. D., Osório, F. D. L., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2015-1701 · Cited by 175
Ayahuasca Shamanism in the Amazon and Beyond
(2014) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199341191.001.0001 · Cited by 174
Antidepressant-like effect of harmane and other β-carbolines in the mouse forced swim test
Farzin, D., & Mansouri, N. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.08.005 · Cited by 171
Following the trace of elusive amines
Premont, R. T., Gainetdinov, R. R., & Caron, M. G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181356198 · Cited by 160
Callaway, J. C., Raymon, L. P., Hearn, W. L., McKenna, D. J., Grob, C. S., Brito, G. S., & Mash, D. C. (1996) · Journal of Analytical Toxicology · doi:10.1093/jat/20.6.492 · Cited by 160
Huot, P., Johnston, T. H., Darr, T., Hazrati, L., Visanji, N. P., Pires, D., Brotchie, J. M., & Fox, S. H. (2010) · Movement Disorders · doi:10.1002/mds.23083 · Cited by 153
Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics
Miksys, S. L., Rao, Y., Hoffmann, E. B., Mash, D. C., & Tyndale, R. F. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01069.x · Cited by 150
Observations on the fate of indolalkylamines in the organism
Erspamer, V. (1955) · The Journal of Physiology · doi:10.1113/jphysiol.1955.sp005242 · Cited by 149
Elevation of blood β-carboline alkaloids in essential tremor
Louis, E. D., Zheng, W., Jurewicz, E. C., Watner, D., Chen, J., Factor-Litvak, P. R., & Parides, M. K. (2002) · Neurology · doi:10.1212/01.wnl.0000038385.60538.19 · Cited by 148
Samoylenko, V., Rahman, M. M., Tekwani, B. L., Tripathi, L. M., Wang, Y.-H., Khan, S. I., Khan, I. A., Miller, L. S., Joshi, V. C., & Muhammad, I. (2010) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2009.10.030 · Cited by 148
Agonist Properties of N,N-Dimethyltryptamine at Serotonin 5-HT2A and 5-HT2C Receptors
Smith, R. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00110-5 · Cited by 147
Cozzi, N. V., Gopalakrishnan, A., Anderson, L. L., Feih, J. T., Shulgin, A. T., Daley, P. F., & Ruoho, A. E. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0308-8 · Cited by 144
Sklerov, J., Levine, B., Moore, K. A., King, T., & Fowler, D. (2005) · Journal of Analytical Toxicology · doi:10.1093/jat/29.8.838 · Cited by 144 · cited 3×
“, consumption with 5-MeO-DMT) [171], there are no reports on deaths directly attributed to ayahuasca [22,172].”
BackgroundMethodAutonomic, Neuroendocrine, and Immunological Effects of Ayahuasca
SANTOS, R. G. D., Valle, M., Bouso, J. C., Nomdedeu, J. F., Rodrı́guez-Espinosa, J., McIlhenny, E. H., Barker, S. A., Barbanoj, M. J., & Riba, J. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823607f6 · Cited by 143
Barker, S. A., McIlhenny, E. H., & Strassman, R. (2012) · Drug Testing and Analysis · doi:10.1002/dta.422 · Cited by 142
Pharmacology of ayahuasca administered in two repeated doses
dos Santos, R. G., Grasa, E., Valle, M., Ballester, M. R., Bouso, J. C., Nomdedéu, J. F., Homs, R., Barbanoj, M. J., & Riba, J. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2434-x · Cited by 141
Pharmahuasca: Human Pharmacology of Oral DMT Plus Harmine
Ott, J. (1999) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1999.10471741 · Cited by 140
Developments in harmine pharmacology — Implications for ayahuasca use and drug-dependence treatment
Brierley, D. I., & Davidson, C. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.06.001 · Cited by 138
Callaway, J. C., & Grob, C. S. (1998) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1998.10399712 · Cited by 137
An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function
Fone, K. C. F. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.061 · Cited by 133
The Role of Sigma-1 Receptor, an Intracellular Chaperone in Neurodegenerative Diseases
Penke, B., Fülöp, L., Szűcs, M., & Frecska, E. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170529104323 · Cited by 132
(2008) · PubMed · Cited by 130
Strassman, R. J., Qualls, C. R., & Berg, L. M. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00200-6 · Cited by 130
Dark Classics in Chemical Neuroscience:N,N-Dimethyltryptamine (DMT)
Cameron, L. P., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00101 · Cited by 128
dos Santos, R. G., Balthazar, F. M., Bouso, J. C., & Hallak, J. E. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116652578 · Cited by 125
Yu, A., Idle, J. R., Krausz, K. W., Kupfer, A., & Gonzalez, F. J. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.047050 · Cited by 123
The psychedelic model of schizophrenia: the case of N,N- dimethyltryptamine
Gillin, J. C., Kaplan, J., Stillman, R. C., & Wyatt, R. J. (1976) · American Journal of Psychiatry · doi:10.1176/ajp.133.2.203 · Cited by 123
A case of β-carboline alkaloid intoxication following ingestion of Peganum harmala seed extract
Frison, G., Favretto, D., Zancanaro, F., Fazzin, G., & Ferrara, S. D. (2008) · Forensic Science International · doi:10.1016/j.forsciint.2008.05.003 · Cited by 118
N,N-Dimethyltryptamine: An Endogenous Hallucinogen
Barker, S. A., Monti, J. A., & Christian, S. T. (1981) · International review of neurobiology · doi:10.1016/s0074-7742(08)60291-3 · Cited by 113
Ayahuasca in Adolescence: A Preliminary Psychiatric Assessment
Da Silveira, D. X., Grob, C. S., de Rios, M. D., Lopez, E., Alonso, L. K., Tacla, C., & Doering-Silveira, E. (2005) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2005.10399792 · Cited by 113
Health status of ayahuasca users
Barbosa, P. C. R., Mizumoto, S., Bogenschutz, M. P., & Strassman, R. J. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1383 · Cited by 112
dos Santos, R. G., & Hallak, J. E. C. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.12.001 · Cited by 111
The involvement of the sigma-1 receptor in neurodegeneration and neurorestoration
Ruscher, K., & Wieloch, T. W. (2014) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2014.11.011 · Cited by 110
Sigma-1 receptor: The novel intracellular target of neuropsychotherapeutic drugs
Hayashi, T. (2014) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2014.07.001 · Cited by 110
Harmine and Imipramine Promote Antioxidant Activities in Prefrontal Cortex and Hippocampus
Réus, G. Z., Stringari, R. B., de Souza, B., Petronilho, F., Dal-Pizzol, F., Hallak, J. E., Zuardi, A. W., Crippa, J. A., & Quevedo, J. (2010) · Oxidative Medicine and Cellular Longevity · doi:10.4161/oxim.3.5.13109 · Cited by 110
Frecska, E., Szabo, A., Winkelman, M. J., Luna, L. E., & McKenna, D. J. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-1024-y · Cited by 109 · cited 1×
“These consist, on one hand, of the inhibition of pro-inflammatory cytokines (IL-1β, IL-6, TNFα) production, and on the other of the enhanced release of anti-inflammatory cytokine IL-10 [204].”
BackgroundClassical hallucinogens and neuroimaging: A systematic review of human studies
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.10.026 · Cited by 107
Psychotomimetic drugs and brain 5-hydroxytryptamine metabolism
Freedman, D. X., Gottlieb, R. M., & Lovell, R. A. (1970) · Biochemical Pharmacology · doi:10.1016/0006-2952(70)90378-3 · Cited by 106
Volpi-Abadie, J., Kaye, A. M., & Kaye, A. D. (2013) · PubMed · Cited by 105
Riba, J., McIlhenny, E. H., Bouso, J. C., & Barker, S. A. (2014) · Drug Testing and Analysis · doi:10.1002/dta.1685 · Cited by 104
WINSTOCK, A. R., Kaar, S. J., & Borschmann, R. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113513852 · Cited by 104
Pic‐Taylor, A., da Motta, L. G., de Morais, J. A., Melo, W., Santos, A. D. F. A., Campos, L. A., Mortari, M. R., von Zuben, M. V., & Caldas, E. D. (2015) · Behavioural Processes · doi:10.1016/j.beproc.2015.05.004 · Cited by 102
Riba, J., McIlhenny, E. H., Valle, M., Bouso, J. C., & Barker, S. A. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1344 · Cited by 102
HALLUCINOGENIC DRUGS OF THE INDOLEALKYLAMINE TYPE AND CENTRAL MONOAMINE NEURONS
Andén, N., CORRODI, H., & Fuxé, K. (1971) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29027-9 · Cited by 101
Dinis‐Oliveira, R. J., Pereira, C. L., & da Silva, D. D. (2018) · Current Molecular Pharmacology · doi:10.2174/1874467211666181010154139 · Cited by 101
Self-citationThe Therapeutic Use of Ayahuasca
Labate, B., & Cavnar, C. (2014) · Springer eBooks · doi:10.1007/978-3-642-40426-9 · Cited by 99
Plants with neurobiological activity as potential targets for drug discovery
Gomes, N. G. M., Campos, M. G., Órfão, J., & Ribeiro, C. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.07.033 · Cited by 99
Self-citationExperiences of encounters with Ayahuasca–“the vine of the soul”
Kjellgren, A., Eriksson, A., & Norlander, T. (2009) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2009.10399767 · Cited by 97
Tolerance and cross-tolerance among psychotomimetic drugs
Appel, J. B., & Freedman, D. X. (1968) · Psychopharmacology · doi:10.1007/bf00401404 · Cited by 96
Bouso, J. C., Fábregas, J. M., Antonijoan, R. M., Rodríguez-Fornells, A., & Riba, J. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3167-9 · Cited by 96
Speranza, L., Labus, J., Volpicelli, F., Guseva, D., Lacivita, E., Leopoldo, M., Bellenchi, G. C., di Porzio, U., Bijata, M., Perrone‐Capano, C., et al. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.13962 · Cited by 93
Yritia, M., Riba, J., Ortuño, J., Ramirez, A., Castillo, A., Alfaro, Y., de la Torre, R., & Barbanoj, M. J. (2002) · Journal of Chromatography B · doi:10.1016/s1570-0232(02)00397-5 · Cited by 90
Therapeutic Potential of 5-HT6Receptor Agonists
Karila, D., Fréret, T., Bouët, V., Boulouard, M., Dallemagne, P., & Rochais, C. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00179 · Cited by 90
Franzen, F., & Gross, H. (1965) · Nature · doi:10.1038/2061052a0 · Cited by 88
Effect of some indolealkylamines on man
TURNER, W. J. (1959) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1959.02340130141020 · Cited by 88
Role of the Serotonergic System in the Pathogenesis of Major Depression and Suicidal Behavior
Mann, J. J. (1999) · Neuropsychopharmacology · doi:10.1038/sj.npp.1395364 · Cited by 88
Hypotheses Regarding the Mechanisms of Ayahuasca in the Treatment of Addictions
Liester, M. B., & Prickett, J. I. (2012) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2012.704590 · Cited by 87
Drucker, G. E., Raikoff, K., Neafsey, E. J., & Collins, M. A. (1990) · Brain Research · doi:10.1016/0006-8993(90)90318-6 · Cited by 83
Lawn, W., Hallak, J. E. C., Crippa, J. A. S., SANTOS, R. G. D., Porffy, L., Barratt, M. J., Ferris, J., WINSTOCK, A. R., & Morgan, C. J. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-14700-6 · Cited by 83
Do hallucinogens cause residual neuropsychological toxicity?
Halpern, J. H., & Pope, H. G. (1999) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00129-x · Cited by 82
Pires, A. P. S., de Oliveira, C. D. R., Moura, S., Dörr, F. A., Silva, W. A. E., & Yonamine, M. (2009) · Phytochemical Analysis · doi:10.1002/pca.1110 · Cited by 79
Dai, F., Chen, Y., Song, Y., Huang, L., Zhai, D., Dong, Y., Lai, L., Zhang, T., Li, D., Pang, X., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052162 · Cited by 77
Acquired and Crossed Tolerance to Mescaline, LSD-25, and BOL-148
Balestrieri, A. (1959) · Archives of General Psychiatry · doi:10.1001/archpsyc.1959.03590030063008 · Cited by 76
Kikura‐Hanajiri, R., Hayashi, M., Saisho, K., & Goda, Y. (2005) · Journal of Chromatography B · doi:10.1016/j.jchromb.2005.01.041 · Cited by 75
Fish, M. S., Johnson, N. M., Lawrence, E. P., & Horning, E. C. (1955) · Biochimica et Biophysica Acta · doi:10.1016/0006-3002(55)90150-5 · Cited by 74
In vivo metabolism of 5-methoxy-N, N-dimethyltryptamine and N,N-dimethyltryptamine in the rat
Sitaram, B. R., Lockett, L., Talomsin, R., Blackman, G. L., & McLeod, W. R. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90118-3 · Cited by 74
Hydroxylation and N-demethylation of N,N-dimethyltryptamine
Szára, S., & Axelrod, J. L. (1959) · Cellular and Molecular Life Sciences · doi:10.1007/bf02158111 · Cited by 74
Wang, Y., Samoylenko, V., Tekwani, B. L., Khan, I. A., Miller, L. S., Chaurasiya, N. D., Rahman, M. M., Tripathi, L. M., Khan, S. I., Joshi, V. C., et al. (2010) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2010.02.013 · Cited by 74
Biochemistry and Pharmacology of Tryptamines and β-Carbolines A Minireview
McKenna, D. J., & Towers, G. H. N. (1984) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1984.10472305 · Cited by 73
Ayahuasca in Adolescence: A Neuropsychological Assessment
Doering-Silveira, E., López, E., Grob, C. S., de Ríos, M. D., Alonso, L. K., Tacla, C., Shirakawa, I., Bertolucci, P. H. F., & da Silveira, D. X. (2005) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2005.10399791 · Cited by 72
Buckholtz, N. S., & Boggan, W. O. (1977) · Life Sciences · doi:10.1016/0024-3205(77)90190-4 · Cited by 72
Dimethyltryptamine (DMT): Subjective effects and patterns of use among Australian recreational users
Cakic, V., Potkonyak, J., & Marshall, A. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.03.015 · Cited by 72
Metabolism of the hallucinogen N,N-dimethyltryptamine in rat brain homogenates
Barker, S. A., Monti, J. A., & Christian, S. T. (1980) · Biochemical Pharmacology · doi:10.1016/0006-2952(80)90169-0 · Cited by 70
Kaplan, J., MANDEL, L. R., Stillman, R. C., Walker, R. W., VandenHeuvel, W. J. A., Gillin, J. C., & Wyatt, R. J. (1974) · Psychopharmacology · doi:10.1007/bf00421376 · Cited by 70
5-Methoxy-N,N-Diisopropyltryptamine-Induced Flashbacks
Akifumi, I., SEKIGUCHI, K., Fujita, K.-I., Yamadera, H., & Koga, Y. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.4.815 · Cited by 69
Carbonaro, T. M., Eshleman, A. J., Forster, M. J., Cheng, K., Rice, K. C., & Gatch, M. B. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3658-3 · Cited by 67
DeSteno, D. A., & Schmauss, C. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.01.012 · Cited by 66
The serotonin receptor 7 and the structural plasticity of brain circuits
Volpicelli, F., Speranza, L., di Porzio, U., Crispino, M., & Perrone‐Capano, C. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00318 · Cited by 66
SANTOS, R. G. D., & Hallak, J. E. C. (2019) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2019.04.053 · Cited by 66
Blier, P. U., & de Montigny, C. (1990) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199000157-00006 · Cited by 64
Zhao, T., Zheng, S., Zhang, B., Li, Y., Bligh, S. W. A., Wang, C., & Wang, Z. (2012) · Food Chemistry · doi:10.1016/j.foodchem.2012.03.024 · Cited by 62
Katchborian-Neto, A., Santos, W. T., Nicácio, K. J., Corrêa, J. O. A., Murgu, M., Martins, T. M. M., Gomes, D. A., Goes, A. M., Soares, M. G., Dias, D. F., et al. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112743 · Cited by 62
The effect of N,N-dimethyltryptamine in human subjects tolerant to lysergic acid diethylamide
Rosenberg, D. E., Isbell, H., Miner, E. J., & Logan, C. R. (1964) · Psychopharmacology · doi:10.1007/bf00413244 · Cited by 61
Solar retinopathy from sun-gazing under the influence of LSD.
Schatz, H., & Mendelblatt, F. I. (1973) · British Journal of Ophthalmology · doi:10.1136/bjo.57.4.270 · Cited by 60
Indolealkylamines: Biotransformations and Potential Drug–Drug Interactions
Yu, A. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9028-5 · Cited by 60
Determination of Designer Drug Cross-Reactivity on Five Commercial Immunoassay Screening Kits
Regester, L. E., Chmiel, J. D., Holler, J. M., Vorce, S. P., LEVINE, B. S., & Bosy, T. Z. (2014) · Journal of Analytical Toxicology · doi:10.1093/jat/bku133 · Cited by 60
Methodology for determining major constituents of ayahuasca and their metabolites in blood
McIlhenny, E. H., Riba, J., Barbanoj, M. J., Strassman, R. J., & Barker, S. A. (2011) · Biomedical Chromatography · doi:10.1002/bmc.1657 · Cited by 59
Chemical composition of traditional and analog Ayahuasca
Kaasik, H., Souza, R. C. Z., Zandonadi, F. S., Tófoli, L. F., & Sussulini, A. (2021) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1815911 · Cited by 59
Christian, S. T., Harrison, R., Quayle, E., Pagel, J., & Monti, J. (1977) · Biochemical Medicine · doi:10.1016/0006-2944(77)90088-6 · Cited by 58
Colaço, C. S., Alves, S. S., Nolli, L. M., Pinheiro, W. O., de Oliveira, D. G. R., Santos, B. W. L., Pic-Taylor, A., Mortari, M. R., & Caldas, E. D. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00547-w · Cited by 58
Gallimore, A. R., & Strassman, R. J. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00211 · Cited by 56
Blier, P. U., & de Montigny, C. (1990) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199001001-00006 · Cited by 56
Identification of N,N‐dimethyltryptamine and β‐carbolines in psychotropic ayahuasca beverage
Gambelunghe, C., Aroni, K., Rossi, R., Moretti, L. D., & Bacci, M. (2008) · Biomedical Chromatography · doi:10.1002/bmc.1023 · Cited by 55
The Identity of the Malpighiaceous Narcotics of South America
Schultes, R. E. (1957) · Botanical Museum leaflets Harvard University · doi:10.5962/p.168508 · Cited by 55
McIlhenny, E. H., Riba, J., Barbanoj, M. J., Strassman, R. J., & Barker, S. A. (2010) · Biomedical Chromatography · doi:10.1002/bmc.1551 · Cited by 53
de Castro-Neto, E. F., da Cunha, R. H., da Silveira, D. X., Yonamine, M., Gouveia, T. L. F., Cavalheiro, É. A., Amado, D., & Naffah‐Mazzacoratti, M. D. G. (2013) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v4.i4.141 · Cited by 52
Lanaro, R., Calemi, D. B. D. A., Togni, L. R., Costa, J. L., Yonamine, M., Cazenave, S. O. S., & Linardi, A. (2015) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2015.1013202 · Cited by 52
Behavioral profile of constituents in ayahuasca, an Amazonian psychoactive plant mixture
Freedland, C. S., & Mansbach, R. S. (1999) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00154-9 · Cited by 51
Severe Solar Maculopathy Associated with the use of Lysergic Acid Diethylamide (LSD)
Fuller, D. G. (1976) · American Journal of Ophthalmology · doi:10.1016/0002-9394(76)90295-6 · Cited by 50
Iurlo, M., Leone, M. G., Schilström, B., Linnér, L., Nomikos, G. G., Hertel, P., Silvestrini, B., & Svensson, T. (2001) · Psychopharmacology · doi:10.1007/s002130100879 · Cited by 49
Tremorigenic Effect and Inhibition of Tryptamine and Serotonin Receptor Binding by β‐Carbolines
Airaksinen, M. M., Lecklin, A., Saano, V., Tuomisto, L. M., & Gynther, J. (1987) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1987.tb01711.x · Cited by 48
Biomedical analysis of New Psychoactive Substances (NPS) of natural origin
Faro, A. F. L., Trana, A. D., Maida, N. L., Tagliabracci, A., Giorgetti, R., & Busardò, F. P. (2019) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2019.112945 · Cited by 48
Toxicological Aspects and Determination of the Main Components of Ayahuasca: A Critical Review
Simão, A. Y., Gonçalves, J., Duarte, A. P., Barroso, M., Cristóvão, A. C., & Gallardo, E. (2019) · Medicines · doi:10.3390/medicines6040106 · Cited by 45
Pichini, S., Marchei, E., García‐Algar, Ó., Gómez, A., Giovannandrea, R. D., & Pacifici, R. (2014) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2014.08.006 · Cited by 44
Maternal and developmental toxicity of ayahuasca in Wistar rats
de Oliveira, C. D. R., Moreira, C. Q., de Sá, L. R. M., Spinosa, H. D. S., & Yonamine, M. (2010) · Birth Defects Research Part B Developmental and Reproductive Toxicology · doi:10.1002/bdrb.20244 · Cited by 44
A Mescaline Associated Fatality
Reynolds, P. C., & Jindrich, E. (1985) · Journal of Analytical Toxicology · doi:10.1093/jat/9.4.183 · Cited by 43
Failure of N,N-dimethyltryptamine to evoke tolerance in cats.
Gillin, J. C., Cannon, E. A., Magyar, R. L., Schwartz, M., & Wyatt, R. J. (1973) · PubMed · Cited by 43
Souza, R. C. Z., Zandonadi, F. D. S., Freitas, D. P., Tófoli, L. F., & Sussulini, A. (2019) · Journal of Chromatography B · doi:10.1016/j.jchromb.2019.06.014 · Cited by 43
Cohen, I., & Vogel, W. H. (1972) · Biochemical Pharmacology · doi:10.1016/0006-2952(72)90119-0 · Cited by 42
Frankel, P. S., & Cunningham, K. A. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03548-5 · Cited by 41
Gaujac, A., Navickiene, S., Collins, M. I., Brandt, S. D., & de Andrade, J. B. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1343 · Cited by 40
Blood dimethyltryptamine concentrations in psychotic disorders.
Lipinski, J. F., MANDEL, L. R., Hs, A., Heuvel, W. J. A. V., & Rw, W. (1974) · PubMed · Cited by 39
Kaasik, H., & Kreegipuu, K. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1748773 · Cited by 37
Arunotayanun, W., & Gibbons, S. (2012) · Natural Product Reports · doi:10.1039/c2np20068f · Cited by 35
Sitaram, B. R., Lockett, L., Blackman, G. L., & McLeod, W. R. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90159-6 · Cited by 35
Dobkin de Rios, M. (1971) · International Journal of Social Psychiatry · doi:10.1177/002076407101700402 · Cited by 35
Fast and Slow Metabolizers of Hoasca
Callaway, J. C. (2005) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2005.10399797 · Cited by 34
Chilcoat, H. D., & Schütz, C. G. (1996) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(96)01297-5 · Cited by 34
The effects of N,N-dimethyltryptamine on operant behavior in squirrel monkeys
Cole, J. M., & Pieper, W. A. (1973) · Psychopharmacology · doi:10.1007/bf00422642 · Cited by 34
Syrian rue tea: A recipe for disaster
Yürüktümen, A., Karaduman, S., Bengi, F., & Fowler, J. (2008) · Clinical Toxicology · doi:10.1080/15563650701323205 · Cited by 34
Ayahuasca: An ancient sacrament for treatment of contemporary psychiatric illness?
Malcolm, B., & Lee, K. C. (2017) · Mental Health Clinician · doi:10.9740/mhc.2017.01.039 · Cited by 34
Suicide During an LSD Reaction
KEELER, M. H., & Reifler, C. B. (1967) · American Journal of Psychiatry · doi:10.1176/ajp.123.7.884 · Cited by 33
Labate, B. C. (2011) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2011.566498 · Cited by 33
de Oliveira, C. D. R., Okai, G. G., Costa, J. L., de Almeida, R. M., Oliveira‐Silva, D., & Yonamine, M. (2012) · Bioanalysis · doi:10.4155/bio.12.124 · Cited by 33
Ayahuasca and cancer treatment
Schenberg, E. E. (2013) · SAGE Open Medicine · doi:10.1177/2050312113508389 · Cited by 33
Örlefors, H., Sundín, A., Fasth, K. J., Öberg, K., Långström, B., Eriksson, B., & Bergström, M. (2003) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(03)00034-9 · Cited by 33
Lesiak, A. D., & Musah, R. A. (2016) · Forensic Science International · doi:10.1016/j.forsciint.2016.06.009 · Cited by 33
Gaujac, A., Dempster, N. M., Navickiene, S., Brandt, S. D., & de Andrade, J. B. (2013) · Talanta · doi:10.1016/j.talanta.2013.01.017 · Cited by 30
A Longitudinal Study of Urinary Excretion of N,N,-Dimethyltryptamine in Psychotic Patients
Checkley, S. A., Murray, R. M., Oon, M. C. H., Rodnight, R., & Birley, J. L. T. (1980) · The British Journal of Psychiatry · doi:10.1192/bjp.137.3.236 · Cited by 30
Wang, Y., Wang, H., Zhang, L., Zhang, Y., Sheng, Y., Deng, G., Li, S., Cao, N., Guan, H., Cheng, X. M., et al. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.111866 · Cited by 29
Grammenos, D., & Barker, S. A. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1329-5 · Cited by 28
Randić, M., & Padjen, A. L. (1971) · Nature · doi:10.1038/230532a0 · Cited by 27
Peganum harmala intoxication, a case report.
Moshiri, M., Etemad, L., Javidi, S., & Alizadeh, A. (2013) · Europe PMC (PubMed Central) · Cited by 27
Rabbit Serum Monoamine Oxidase
McEwen, C. M., & Sober, A. J. (1967) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)95934-x · Cited by 26
THE EFFECT OF AMINE OXIDASE INHIBITORS ON PREGNANCY
POULSON, E., & Robson, J. M. (1963) · Journal of Endocrinology · doi:10.1677/joe.0.0270147 · Cited by 26
Yanai, K., Ido, T., Ishiwata, K., Hatazawa, J., Takahashi, T., Iwata, R., & Matsuzawa, T. (1986) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/bf00276707 · Cited by 24
The “Vine of the Soul” vs. The Controlled Substances Act: Implications of the Hoasca Case
Bullis, R. K. (2008) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2008.10400630 · Cited by 24
Effects of 5-HT2A Receptor Stimulation and Blocking on Immune Response
Давыдова, С. М., Чейдо, М. А., Gevorgyan, M. M., & Idova, G. V. (2010) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-010-1109-7 · Cited by 24
Li, S., Zhang, Y., Deng, G., Wang, Y., Qi, S., Cheng, X. M., Ma, Y., Xie, Y., & Wang, C. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00541 · Cited by 24
Colaço, C. S., Alves, S. S., Nolli, L. M., Pinheiro, W. O., de Oliveira, D. G. R., Santos, B. W. L., Taylor, A. P., Mortari, M. R., & Caldas, E. D. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00854-w · Cited by 23
Personality Traits in Former Spanish Substance Users Recovered with Ayahuasca
Apud Peláez, I. E. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1752960 · Cited by 22
Shah, N. S., & Hedden, M. P. (1978) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(78)90070-9 · Cited by 22
Indolethylamine‐N‐methyltransferase in developing rabbit lung
Lin, R.-L., Sargeant, S., & Narasimhachari, N. (1974) · Developmental Psychobiology · doi:10.1002/dev.420070511 · Cited by 21
Flagged first, then by citations
1 of the 218 references couldn’t be matched to a known paper.
Research works printed but not linked: 12
- Strassman, R.J. (2001). DMT: The Spirit Molecule: A Doctor’s Revolutionary Research into the Biology of Near-Death and Mystical Experiences, Park Street Press.
- Rall, T.W., Nies, A.S., and Taylor, P. (1990). Drug addiction and drug abuse. Goodman and Gilman’s the Pharmacological Basis of Therapeutics, McGraw-Hill.
- Hardman, J.G., Limbird, L.E., Molinoff, P.B., Ruddon, R.W., and Gilman, A.G. (2018). Drug Use Disorders and Addiction. Goodman and Gilman’s the Pharmacological Basis of Therapeutics, McGraw-Hill.
- Hofmann, A. (1976). LSD—My Problem Child, McGraw-Hill.
- Schultes, 1972, Ethnotoxocological significance of additives to New World hallucinogens, Plant Sci. Bull., 18, 34
- Moffat, A.C., Osselton, M.D., Widdop, B., and Watts, J. (2011). Clarke’s Analysis of Drugs and Poisons, Pharmaceutical Press. [4th ed.].
- National Center for Biotechnology Information (2020, July 29). PubChem Compound Summary for CID 6089, N,N-Dimethyltryptamine, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/N_N-Dimethyltryptamine.
- National Center for Biotechnology Information (2020, July 29). PubChem Compound Summary for CID 3564, Harmaline, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/Harmaline.
- National Center for Biotechnology Information (2020, July 29). PubChem Compound Summary for CID 159809, Tetrahydroharmine, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/Tetrahydroharmine.
- Naranjo, 1959, Estudio comparativo de la harmina, la dietilamida del ácido lisérgico (LSD-25) y la mescalina, Rev. Confed. Médica Panam., 6, 1
- Warren, 2004, Fatal nicotine intoxication resulting from the ingestion of “ayahuasca”, J. Anal. Toxicol., 28, 287
- Metzner, R. (1999). The psychology of ayahuasca. Ayahuasca: Hallucinogens, Consciousness, and the Spirit of Nature, Thunder’s Mouth Press.
Cited by
Sorted by citations
D’Souza, D. C., Syed, S. A., Flynn, L. T., Safi-Aghdam, H., Cozzi, N. V., & Ranganathan, M. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01344-y · Cited by 162
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Zaretsky, T. G., Jagodnik, K. M., Barsic, R., Antonio, J. H., Bonanno, P. A., MacLeod, C., Pierce, C., Carney, H., Morrison, M. T., Saylor, C. F., et al. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666231027111147 · Cited by 92
Drug–drug interactions involving classic psychedelics: A systematic review
Halman, A., Kong, G., Sarris, J. J., & Perkins, D. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231211219 · Cited by 78
Biosynthesis and synthetic biology of psychoactive natural products
Jamieson, C. S., Misa, J., Tang, Y., & Billingsley, J. M. (2021) · Chemical Society Reviews · doi:10.1039/d1cs00065a · Cited by 74
Rosenblat, J. D., Husain, M. I., Lee, Y. L., McIntyre, R. S., Mansur, R. B., Castle, D. J., Offman, H., Parikh, S. V., Frey, B. N., Schaffer, A., et al. (2022) · The Canadian Journal of Psychiatry · doi:10.1177/07067437221111371 · Cited by 68
Metadata
- Authors
- Brito-da-Costa, A. M., Dias-da-Silva, D., Gomes, N. G. M., Dinis-Oliveira, R. J., & Madureira-Carvalho, Á.
- Affiliations
- Cooperativa de Ensino Superior Politécnico e Universitário (PT)
- Department of Sciences, IINFACTS-Institute of Research and Advanced Training in Health Sciences and Technologies, University Institute of Health Sciences (IUCS), CESPU, CRL, 4585-116 Gandra, Portugal
- Universidade do Porto (PT)
- ORCID
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2020-10-23
- Volume
- 13
- Issue
- 11
- Pages
- 334
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC7690791
- OpenAlex
- W3094461574
- Cited by
- 117
- References
- 218
- Citations by year
- 2026: 13 · 2025: 24 · 2024: 25 · 2023: 22 · 2022: 25 · 2021: 7
- FWCI
- 1.06
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
- Keywords
- ayahuasca, N,N-dimethyltryptamine, harmine, harmaline, tetrahydroharmine, harmala alkaloids, toxicokinetics, toxicodynamics, monoamine oxidase A inhibition, Psychotria viridis, Banisteriopsis caapi, 5-HT2A receptor, forensic toxicology, psychedelic therapy, depression, anxiety, substance use disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review